lorviqua
pfizer europe ma eeig - lorlatinib - karcinóma, nem kissejtes tüdő - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
orserdu
stemline therapeutics b.v. - elacestrant - mellnövekedés - endokrin terápia - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
erlotinib teva 25 mg filmtabletta
teva gyógyszergyár zrt. - erlotinib -
erlotinib teva 100 mg filmtabletta
teva gyógyszergyár zrt. - erlotinib -
erlotinib teva 150 mg filmtabletta
teva gyógyszergyár zrt. - erlotinib -
lapatinib teva 250 mg filmtabletta
teva gyógyszergyár zrt. - lapatinib ditosilate monohydrate -
erlotinib ratiopharm 25 mg filmtabletta
teva gyógyszergyár zrt. - erlotinib -
erlotinib ratiopharm 100 mg filmtabletta
teva gyógyszergyár zrt. - erlotinib -
erlotinib ratiopharm 150 mg filmtabletta
teva gyógyszergyár zrt. - erlotinib -
erlotinib hexal 25 mg filmtabletta
hexal ag - erlotinib -